Compare MSA & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSA | COGT |
|---|---|---|
| Founded | 1914 | 2014 |
| Country | United States | United States |
| Employees | 5300 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.0B |
| IPO Year | N/A | 2018 |
| Metric | MSA | COGT |
|---|---|---|
| Price | $159.89 | $33.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | ★ $197.40 | $36.21 |
| AVG Volume (30 Days) | 299.4K | ★ 2.2M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,871,000.00 |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $5.00 | $1,733.58 |
| P/E Ratio | $28.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $151.11 | $6.93 |
| 52 Week High | $208.92 | $43.73 |
| Indicator | MSA | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 48.42 |
| Support Level | $158.45 | $30.87 |
| Resistance Level | $165.15 | $37.69 |
| Average True Range (ATR) | 4.03 | 1.49 |
| MACD | -0.68 | 0.03 |
| Stochastic Oscillator | 22.08 | 42.43 |
MSA Safety Inc makes safety products that are used to protect workers in the oil and gas and mining industries. The company's product offerings include breathing apparatuses, fall protection, portable gas detection systems, industrial head protection, fire and rescue helmets, and fixed gas and flame detection systems, among others. The end markets for its products include the fire service, contractor, industrial, mining, oil and gas, and utilities industries. The company has organized its business into four geographical operating segments that are aggregated into two reportable segments: Americas and International. The majority of its revenue is generated from the Americas segment, which is comprised of the company's operations in Northern North America and Latin America geographies.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.